Sandbox Reserved 1106
From Proteopedia
Line 46: | Line 46: | ||
==== GW motifs ==== | ==== GW motifs ==== | ||
- | The hAGO1 protein has a single GW binding site. This site is able to bind to GW/WG motifs of other proteins, such as GW182. It is contained in the PIWI domain, also found in AGO2. Proteins like GW182 form with their GW motif a “hook” which interacts with the PIWI domain and enables the docking of the protein in a tryptophan-binding pocket of AGO1. This interaction is enhanced through the binding of an miRNA to AGO1, which ensures that mature RISC can be recruited efficiently for silencing. Through this kind of interaction, several AGO1 proteins can bind to a single protein with GW motifs. | + | The hAGO1 protein has a single GW binding site. This site is able to bind to GW/WG motifs of other proteins, such as GW182. It is contained in the PIWI domain, also found in AGO2. Proteins like GW182 form with their GW motif a “hook” which interacts with the PIWI domain and enables the docking of the protein in a tryptophan-binding pocket of AGO1. This interaction is enhanced through the binding of an miRNA to AGO1, which ensures that mature RISC can be recruited efficiently for silencing. Through this kind of interaction, several AGO1 proteins can bind to a single protein with GW motifs. <ref name="source9">Elad Elkayam, et al. (2017, August). ''Multivalent recruitment of human argonaute by GW182''. Molecular Cell, 646-658. [https://www.sciencedirect.com/science/article/pii/S1097276517305014] </ref> |
==== DDB2 and Ago 1 complex ==== | ==== DDB2 and Ago 1 complex ==== | ||
- | In the case of UV-irradiation response, it has been shown that AGO1 can form complexes with DNA Damage Binding (DDB) proteins and uviRNAs. The specific mechanisms of binding and binding sites have not yet been uncovered. | + | In the case of UV-irradiation response, it has been shown that AGO1 can form complexes with DNA Damage Binding (DDB) proteins and uviRNAs. The specific mechanisms of binding and binding sites have not yet been uncovered. <ref name="source10"> Schalk C. et al. (2017, February). ''Small RNA-mediated repair of UV-induced DNA lesions by the DNA damagebinding protein 2 and Argonaute 1''. Proc. Natl Acad. Sci. (PNAS) USA 114, E2965–E2974.[https://www.pnas.org/content/early/2017/03/20/1618834114]</ref> |
=== Mutations domains === | === Mutations domains === | ||
Line 56: | Line 56: | ||
==== Restoration of slicing activity ==== | ==== Restoration of slicing activity ==== | ||
- | Among the four human Argonaute proteins, only hAGO2 is an active slicer. A conserved catalytic triad within the PIWI domain in hAGO2 is required for its slicing activity and hAGO1 has an arginine in place of the active site histidine in the DEDH tetrad. Yet, restoring an intact catalytic DEDH tetrad with a R805H mutation is not enough to activate slicing in hAGO1. Therefore, it appears more distant regions of the enzyme are determinant for slicer activity. Domain-swapping experiments revealed that the substitution of the hAGO1 and hAGO2 PIWI domain activates hAGO1 while hAGO2 slicing activity is being removed; providing new evidence that other factors, in addition to the incomplete DEDH tetrad, are responsible for the slicer defect in hAGO1. Indeed, an additional mutation of L674F on the PIWI loop 3 adjacent to the active site of hAGO1 leads to an active slicer with level comparable to that of the hAGO2 PIWI domain swap. Intriguingly, the elements that make hAGO1 an active slicer involve a sophisticated interplay between the active site and more distant regions of the enzyme. <ref name="source1" | + | Among the four human Argonaute proteins, only hAGO2 is an active slicer. A conserved catalytic triad within the PIWI domain in hAGO2 is required for its slicing activity and hAGO1 has an arginine in place of the active site histidine in the DEDH tetrad. Yet, restoring an intact catalytic DEDH tetrad with a R805H mutation is not enough to activate slicing in hAGO1. Therefore, it appears more distant regions of the enzyme are determinant for slicer activity. Domain-swapping experiments revealed that the substitution of the hAGO1 and hAGO2 PIWI domain activates hAGO1 while hAGO2 slicing activity is being removed; providing new evidence that other factors, in addition to the incomplete DEDH tetrad, are responsible for the slicer defect in hAGO1. Indeed, an additional mutation of L674F on the PIWI loop 3 adjacent to the active site of hAGO1 leads to an active slicer with level comparable to that of the hAGO2 PIWI domain swap. Intriguingly, the elements that make hAGO1 an active slicer involve a sophisticated interplay between the active site and more distant regions of the enzyme. <ref name="source1"/> |
+ | |||
== Function == | == Function == | ||
Line 64: | Line 65: | ||
Unlike hAGO2, hAGO1 does not function as an endonuclease that can cleave mRNA molecules within regions that base pair with perfectly complementary siRNAs or miRNAs. The mechanism by which hAGO1 mediates translational repression is still a matter of debate. hAGO1 has been shown to act on translation initiation, on translation elongation and on the degradation of nascent polypeptides. Therefore, the mechanisms by which hAGO1 inhibit translation might depend on the target that is being regulated. Such a model, however, remains to be experimentally proven. | Unlike hAGO2, hAGO1 does not function as an endonuclease that can cleave mRNA molecules within regions that base pair with perfectly complementary siRNAs or miRNAs. The mechanism by which hAGO1 mediates translational repression is still a matter of debate. hAGO1 has been shown to act on translation initiation, on translation elongation and on the degradation of nascent polypeptides. Therefore, the mechanisms by which hAGO1 inhibit translation might depend on the target that is being regulated. Such a model, however, remains to be experimentally proven. | ||
It was shown very recently that upon cell-cycle arrest in human cells, hAGO1 bind to the 3’ UTRs of specific mRNAs and stimulate translation. Interestingly, hAGO1 proteins inhibit | It was shown very recently that upon cell-cycle arrest in human cells, hAGO1 bind to the 3’ UTRs of specific mRNAs and stimulate translation. Interestingly, hAGO1 proteins inhibit | ||
- | translation in proliferating cells and it has therefore been suggested that hAGO1-mediated translational regulation oscillates between repression and activation during the cell cycle. | + | translation in proliferating cells and it has therefore been suggested that hAGO1-mediated translational regulation oscillates between repression and activation during the cell cycle. <ref name="source4"> Ligang Wu, et al. (2008, September). ''Importance of translation and Nonnucleolytic Ago Proteins for On- Target RNA Interference''. Current Biology, 1327-1332.[https://www.cell.com/current-biology/fulltext/S0960-9822(08)01017-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0960982208010178%3Fshowall%3Dtrue] </ref> <ref name="source5"> Lidiya Lisitskaya, et al. (2018). ''DNA Interference and beyond : Structure and Functions of Prokaryotic Argonaute Proteins''. Nature Communications.[https://www.nature.com/articles/s41467-018-07449-7] </ref> |
=== Role in RISC complex === | === Role in RISC complex === | ||
- | The AGO1 protein is part of the RNA-induced silencing complex RISC, which is required in the RNA interference process. In this case, the miRNAs, interacting with hAGO1, bind to partially complementary target sites located in the 3’ unstranslated regions (UTRs) of their specific target mRNAs. Imperfect base pairing between small RNAs and their target mRNAs leads to repression of translation and/or deadenylation (removal of the poly(A) tail) of the target, followed by destabilization of the target, which most probably occurs in P-bodies. | + | The AGO1 protein is part of the RNA-induced silencing complex RISC, which is required in the RNA interference process. In this case, the miRNAs, interacting with hAGO1, bind to partially complementary target sites located in the 3’ unstranslated regions (UTRs) of their specific target mRNAs. Imperfect base pairing between small RNAs and their target mRNAs leads to repression of translation and/or deadenylation (removal of the poly(A) tail) of the target, followed by destabilization of the target, which most probably occurs in P-bodies. <ref name="source4"> Ligang Wu, et al. (2008, September). ''Importance of translation and Nonnucleolytic Ago Proteins for On- Target RNA Interference''. Current Biology, 1327-1332.[https://www.cell.com/current-biology/fulltext/S0960-9822(08)01017-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0960982208010178%3Fshowall%3Dtrue] </ref> <ref name="source6"> Bethany A Jawosky et al. (2006, September). ''Involvement of AGO1 and AGO2 in mammalian transcriptional silencing''. Nature Structural and Molecular biology, 787-792.[https://www.nature.com/articles/nsmb1140] </ref> |
== Applications == | == Applications == | ||
Line 74: | Line 75: | ||
=== Cancer Research === | === Cancer Research === | ||
- | Studies have linked a reduced amount of Argonaute proteins in cells with an increase in tumour development and progression in the case of melanoma. As important parts of miRNA processing, several key cellular processes linked to gene silencing are impacted by the amounts of AGO proteins in the cell. Additionally, although there is few research in the case of AGO1, another Argonaute protein, AGO2, was found to be overexpressed in carcinomas and to be interacting with well-studied tumour factors in regulating the metabolism of the cancer cells | + | Studies have linked a reduced amount of Argonaute proteins in cells with an increase in tumour development and progression in the case of melanoma. As important parts of miRNA processing, several key cellular processes linked to gene silencing are impacted by the amounts of AGO proteins in the cell. Additionally, although there is few research in the case of AGO1, another Argonaute protein, AGO2, was found to be overexpressed in carcinomas and to be interacting with well-studied tumour factors in regulating the metabolism of the cancer cells. <ref name="source7"> Daniel Völler, et al. (2016, August). ''Argonaute family protein expression in normal tissue and cancer entities''. Plos one.[https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161165] </ref> <ref name="source8"> ZhenLong Ye, et al. (2015, July). ''Argonaute 2: A Novel Rising Star in Cancer Research''. Journal of Cancer, 877-882. [https://www.jcancer.org/v06p0877.htm] </ref> |
Revision as of 14:50, 17 January 2020
This Sandbox is Reserved from 25/11/2019, through 30/9/2020 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1091 through Sandbox Reserved 1115. |
To get started:
More help: Help:Editing |
Argonaute 1 (PDB 4KXT)
|
References
[1] Gunter Meister, et al. (2005, December). Identification of Novel Argonaute-Associated Proteins. Current Biology, 2149-2155. [11]
[2] Bethany A Jawosky et al. (2006, September). Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nature Structural and Molecular biology, 787-792.[12]
[3] Ligang Wu, et al. (2008, September). Importance of translation and Nonnucleolytic Ago Proteins for On- Target RNA Interference. Current Biology, 1327-1332.[13]
[4] Christopher R. Faehnle, et al. (2013, May). The making of a Slicer: Activation of Human Argonaute-1. Cell Reports. [14]
[5] Daniel Völler, et al. (2016, August). Argonaute family protein expression in normal tissue and cancer entities. Plos one.[15]
[6] Schalk C. et al. (2017, February). Small RNA-mediated repair of UV-induced DNA lesions by the DNA damagebinding protein 2 and Argonaute 1. Proc. Natl Acad. Sci. (PNAS) USA 114, E2965–E2974.[16]
[7] Elad Elkayam, et al. (2017, August). Multivalent recruitment of human argonaute by GW182. Molecular Cell, 646-658. [17]
[8] Lidiya Lisitskaya, et al. (2018). DNA Interference and beyond : Structure and Functions of Prokaryotic Argonaute Proteins. Nature Communications.[18]
[9] Ena Secic, et al. (2019, October). Further Elucidation of the argonaute and dicer protein families in the model grass species Brachypodium distachyon. Frontiers in Plant Science.[19]
[10] ZhenLong Ye, et al. (2015, July). Argonaute 2: A Novel Rising Star in Cancer Research. Journal of Cancer, 877-882. [20]
JSmol in Proteopedia [11]
- ↑ 1.0 1.1 1.2 Christopher R. Faehnle, et al. (2013, May). The making of a Slicer: Activation of Human Argonaute-1. Cell Reports. [1]
- ↑ Ena Secic, et al. (2019, October). Further Elucidation of the argonaute and dicer protein families in the model grass species Brachypodium distachyon. Frontiers in Plant Science. [2]
- ↑ Gunter Meister, et al. (2005, December). Identification of Novel Argonaute-Associated Proteins. Current Biology, 2149-2155. [3]
- ↑ Elad Elkayam, et al. (2017, August). Multivalent recruitment of human argonaute by GW182. Molecular Cell, 646-658. [4]
- ↑ Schalk C. et al. (2017, February). Small RNA-mediated repair of UV-induced DNA lesions by the DNA damagebinding protein 2 and Argonaute 1. Proc. Natl Acad. Sci. (PNAS) USA 114, E2965–E2974.[5]
- ↑ 6.0 6.1 Ligang Wu, et al. (2008, September). Importance of translation and Nonnucleolytic Ago Proteins for On- Target RNA Interference. Current Biology, 1327-1332.[6]
- ↑ Lidiya Lisitskaya, et al. (2018). DNA Interference and beyond : Structure and Functions of Prokaryotic Argonaute Proteins. Nature Communications.[7]
- ↑ Bethany A Jawosky et al. (2006, September). Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nature Structural and Molecular biology, 787-792.[8]
- ↑ Daniel Völler, et al. (2016, August). Argonaute family protein expression in normal tissue and cancer entities. Plos one.[9]
- ↑ ZhenLong Ye, et al. (2015, July). Argonaute 2: A Novel Rising Star in Cancer Research. Journal of Cancer, 877-882. [10]
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024